Danish and Swedish patients with RA: crude and age- and gender-adjusted IR of serious infections per 100 PY 0–12 months and 0–24 months after starting treatment with abatacept, rituximab or tocilizumab
| Abatacept | Rituximab | Tocilizumab | ||||
| Serious infections, 0–12 months | ||||||
| Country | Denmark | Sweden | Denmark | Sweden | Denmark | Sweden |
| PY | 568 | 1477 | 571 | 2189 | 906 | 1426 |
| Infections, n | 40 | 90 | 50 | 156 | 55 | 65 |
| Crude IR/100 PY (95% CI) | 7.0 (5.2 to 9.6) | 6.1 (5.0 to 7.5) | 8.8 (6.7 to 11.6) | 7.1 (6.1 to 8.3) | 6.1 (4.7 to 7.9) | 4.6 (3.6 to 5.8) |
| Adjusted IR* | 7.1 (5.1 to 9.9) | 6.0 (4.8 to 7.5) | 8.1 (5.9 to 11.0) | 6.4 (5.3 to 7.7) | 6.1 (4.6 to 8.1) | 4.7 (3.7 to 6.1) |
| Serious infections, 0–24 months | ||||||
| PY | 712 | 2183 | 871 | 3579 | 1366 | 2162 |
| Infections, n | 42 | 127 | 69 | 241 | 70 | 90 |
| Crude IR/100 PY (95% CI) | 5.9 (4.4 to 8.0) | 5.8 (4.9 to 6.9) | 7.9 (6.3 to 10.1) | 6.7 (5.9 to 7.6) | 5.1 (4.1 to 6.5) | 4.2 (3.4 to 5.1) |
| Adjusted IR* | 6.1 (4.4 to 8.3) | 5.6 (4.6 to 6.7) | 7.5 (5.8 to 9.7) | 5.8 (5.0 to 6.8) | 5.2 (4.1 to 6.7) | 4.3 (3.4 to 5.3) |
*Adjusted for age and gender.
IR, incidence rate; PY, person years; RA, rheumatoid arthritis.